Long-term, Prospective, Observational, Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy

Trial Profile

Long-term, Prospective, Observational, Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms PASSAGE
  • Sponsors Novartis
  • Most Recent Events

    • 03 Mar 2017 Planned End Date changed from 1 Jun 2020 to 28 Nov 2022.
    • 03 Mar 2017 Planned primary completion date changed from 1 Jun 2020 to 28 Nov 2022.
    • 24 Jul 2012 Planned number of patients changed from 3000 to 3600.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top